Monday, October 29, 2007 3:29:48 PM
Accuray Announces Four New Products at Nation's Leading Radiation Oncology MeetingLast update: 10/29/2007 3:00:00 PMNew CyberKnife Technologies Improve Treatment Times, Optimize Planning Objectives and Offer Increased Clinical Flexibility in Radiation Delivery SUNNYVALE, Calif., Oct 29, 2007 /PRNewswire-FirstCall via COMTEX/ -- Accuray Incorporated (ARAY), a global leader in the field of radiosurgery, announced today four new products designed to improve treatment times, optimize treatment planning objectives and offer greater clinical flexibility in radiation delivery. These products are being launched at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles. Iris(TM) Variable Aperture Collimator In radiosurgery, clinicians can define the amount, or dose, of radiation delivered during treatment using a collimator -- a metal radiation blocking device with an opening that dictates the shape and size of the radiation beam. In the past, when clinicians wanted to use multiple collimators to vary the size and shape of their radiation beam it required they manually switch out collimators in the middle of treatment. With the launch of the CyberKnife System's Xchange(TM) Robotic Collimator Changer at ASTRO 2006, the process of changing collimators became automated, eliminating the need to re-enter the treatment room, which minimizes related treatment delays. Now the process for using multiple collimators has become even more streamlined with the introduction of the Iris(TM) Variable Aperture Collimator, which no longer requires the removal of a collimator because it can automatically alter the size of its opening to let radiation beams of 12 discreet sizes pass through. The Iris Collimator allows the CyberKnife System to efficiently deliver different sized beams from each treatment position (as opposed to delivering with one collimator size from many positions, then switching to a new size to deliver from many positions, then switching to the next size and so on). This makes multiple collimator sized treatments much faster, allowing clinicians to safely deliver such a treatment in as little as half the time. The Iris Collimator enables clinicians to create and deliver practical multi-collimator treatments that have greater accuracy, more uniformity and better avoidance of nearby critical structures and healthy tissue than single collimator treatments. 800 MU/min LINAC Currently the CyberKnife System features a compact linear accelerator capable of delivering 600 monitor units per minute. A monitor unit (MU) is the measure of machine output for a linear accelerator (LINAC) in radiation therapy and radiation dose rate typically is measured in MU/minute. Accuray is announcing the introduction of an 800 MU/min LINAC, which is capable of delivering higher dose rates of radiation to a tumor, thereby reducing treatment times. This advanced new 800 MU/min linear accelerator system will not only be incorporated into the current CyberKnife offering, it will also serve as the platform for future technologies. Sequential Optimization Planning Tool The Sequential Optimization feature is an optimization capability that will now be available as a software option for the MultiPlan(R) Treatment Planning System. The technology allows users to optimize their treatment objectives based on each unique clinical situation using prioritized clinical objectives, instead of the traditional trial and error setting of various constraints to narrow in on an optimized treatment. This enables users to establish their own clinical objectives to achieve high quality, more intuitive treatment planning in a shorter amount of time. RoboCouch(R) Patient Positioning System with Seated Load The RoboCouch(R) Patient Positioning System with a new seated load capability is a more comfortable and ergonomic treatment couch, developed with mobility challenged patients in mind. The seated load feature offers easier loading and unloading capabilities and provides added comfort for the unique needs of wheelchair bound or disabled patients. Its flexible design has a built in adjustable knee bolster improving patient comfort while also allowing treatments to be performed either with the patient's knees bent and up or in a completely flat table top configuration. In addition, because patients are more comfortable during treatment, the system minimizes patient motion resulting in fewer treatment interruptions. While these technologies will positively impact CyberKnife treatments across many indications, they are especially important in the treatment of lung and prostate cancer because they offer the flexibility to tailor treatment with different clinical objectives to each patient -- whether the priority is conformality, homogeneity, reduced dose delivery or some combination -- all while reducing radiation dose to the surrounding critical structures. Additionally, the combination of these technologies will improve patient comfort, speed up treatment delivery and planning times, and improve the accuracy of delivered treatments ultimately ensuring that the right dose is delivered to the right place at the right time. "At Accuray our focus is delivering clinically significant technologies to our current and future CyberKnife System users," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "At this year's ASTRO, we are delighted to be able to launch these four new innovations that not only better meet our clinicians' needs for faster, more flexible radiation optimization, but also enhance their patients' treatment experience." About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively and with sub-millimeter accuracy. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver precise, high-dose radiation, minimizing damage to surrounding healthy tissue and eliminating the need for invasive head or body stabilization frames. About Accuray Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 35,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Amer
THE THRILL OF VICTORY ;-) & THE AGONY OF DEFEAT ;-(
Recent ARAY News
- Accuray Reports Fiscal 2024 Third Quarter Financial Results • PR Newswire (US) • 05/01/2024 08:06:00 PM
- Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 • PR Newswire (US) • 04/25/2024 11:35:00 AM
- Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland • PR Newswire (US) • 04/18/2024 11:35:00 AM
- Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024 • PR Newswire (US) • 04/17/2024 08:05:00 PM
- New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System • PR Newswire (US) • 03/26/2024 11:35:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:15:22 PM
- Accuray Incorporated to Speak at 36th Annual Roth Conference • PR Newswire (US) • 03/04/2024 09:30:00 PM
- Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference • PR Newswire (US) • 02/27/2024 10:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 04:19:22 PM
- Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System • PR Newswire (US) • 02/13/2024 12:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 08:01:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:15:46 PM
- Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference • PR Newswire (US) • 02/05/2024 10:30:00 PM
- Accuray Reports Fiscal 2024 Second Quarter Financial Results • PR Newswire (US) • 01/31/2024 09:06:00 PM
- Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions • PR Newswire (US) • 01/25/2024 12:35:00 PM
- Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024 • PR Newswire (US) • 01/16/2024 10:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:15:14 PM
- Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System • PR Newswire (US) • 12/05/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:51:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:37 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM